Latanoprostene bunod

Class
Antiglaucoma agents
Subclass
Prostaglandin analogs
Substance name
Latanoprostene bunod
Brand names
Vyzulta®
Common formulations
Ophthalmic solution
Dosage and administration
Adults patients
Glaucoma • Open-angle
•
1 gtt OPHTH qHS
Ocular hypertension
•
1 gtt OPHTH qHS
Indications for use
Labeled indications
Adults
•
Treatment of glaucoma (open-angle)
•
Treatment of ocular hypertension
Safety risks
Contraindications
Hypersensitivity to latanoprostene bunod or its components
Active intraocular inflammation
Warnings and precautions
Bacterial keratitis
•
Use caution in patients using multiple-dose containers of topical ophthalmic products, especially in the presence of concurrent corneal disease or a disruption of the ocular epithelial surface.
Contact lens damage, eye irritation
•
Use caution in patients wearing contact lenses, as latanoprost products contain benzalkonium chloride, which contact lenses may absorb. Advise removing contact lenses before administering latanoprost and reinserting 15 minutes after administration.
Exacerbation of herpes simplex keratitis
•
Use caution in patients with a history of herpes simplex keratitis.
Hyperpigmentation
•
Maintain a high level of suspicion, as latanoprost has been associated with an increased risk of iris pigmentation, periorbital hyperpigmentation, eyelash hyperpigmentation, and abnormal eyelash growth.
Macular edema
•
Use caution in patients with aphakia, pseudophakia with a torn posterior lens capsule, or with known risk factors for macular edema.
Uveitis
•
Use caution in patients with a history of uveitis.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
No guidance available.
Renal replacement therapy
Any modality
•
No guidance available.
Hepatic impairment
Any severity
•
No guidance available.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Use only if benefits outweigh potential risks. Evidence of fetal harm in animals.
Breastfeeding
Use with caution during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Common 1-10%
•
Conjunctival injection, eye irritation, eye pain
Unknown frequency
•
Blurred vision, foreign body sensation in the eyes, macular edema, iris hyperpigmentation, periorbital hyperpigmentation, abnormal eyelash growth, superficial punctate keratitis, bacterial keratitis, trichiasis, uveitis, herpes simplex keratitis
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource